Peptides.media

Peptide education

Motixafortide

Aphexda · BL-8040 · BKT140

Motixafortide is a prescription medicine that helps move blood-forming stem cells into the bloodstream for collection. In the United States it is approved with filgrastim for people with multiple myeloma preparing for an autologous stem cell transplant.

FDA

A randomized trial found higher stem cell collection success when motixafortide was added to filgrastim. The label requires premedication and monitoring because serious hypersensitivity can occur.

FDAPMID 37069359

By the Peptides Media Editorial TeamEditorial policy3 min read

U.S. statusApproved for a specific use
SettingAutologous transplant collection
RouteSubcutaneous injection
EvidenceRandomized phase 3 trial

Overview

Quick answer

The approved use is stem cell mobilization, not direct treatment of multiple myeloma. A successful collection endpoint does not by itself show that the medicine improves cancer survival.

FDAPMID 37069359

What is motixafortide approved for?

The FDA indication is use with filgrastim to mobilize stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.

FDA

Does it treat myeloma directly?

The approved indication concerns collection for transplant. The collection trial was not proof that motixafortide itself treats the cancer or extends survival.

FDAPMID 37069359

What did the collection trial show?

In the FDA label's central-laboratory analysis, 67.5% of patients given motixafortide and filgrastim reached the specified cell target in up to two procedures after one dose, versus 9.5% given placebo and filgrastim.

FDA

What are the main precautions?

The label warns of anaphylaxis, other hypersensitivity reactions, injection-site reactions, leukocytosis, possible tumor cell mobilization, and fetal harm. It contraindicates use after a serious hypersensitivity reaction to motixafortide. The transplant team uses premedication and monitors patients after each dose.

FDA

Does an EU orphan designation mean the medicine is approved there?

No. The European Medicines Agency lists an orphan designation for patients undergoing blood-forming stem cell transplantation. The designation is not a marketing authorization and does not by itself establish current EU approval status.

EU orphan designation

Evidence

Evidence snapshot

Clinical trial122 randomized adults

Patients with multiple myeloma received filgrastim with either motixafortide or placebo before stem cell collection.

FDAPMID 37069359
Collection outcomeHigher with motixafortide

The FDA label reports 67.5% versus 9.5% reaching at least 6 million CD34-positive cells per kg in up to two collections after one dose, using central laboratory measurements.

FDA
SafetyHypersensitivity risk

Anaphylactic shock and injection-site reactions are label warnings. Precautions apply even when used for the approved indication.

FDA

Claims

Common claims vs evidence

ClaimHuman evidenceVerdict
Motixafortide can improve stem cell collection before transplant.In GENESIS, the label's central analysis found more patients reached the specified collection target with motixafortide plus filgrastim than with placebo plus filgrastim. Supported for the studied collection endpoint in multiple myeloma, not for every type of transplant or a different patient population.
FDAPMID 37069359
Stem cell collection proves that motixafortide treats myeloma.The randomized endpoint measured the number of cells collected, not direct cancer treatment or a survival improvement attributable to the mobilizing drug. The collection result should not be presented as a cancer cure.
FDAPMID 37069359

Bottom line

Main takeaway

Bottom line

This medicine helps a transplant team collect a patient's own stem cells.

Evidence boundary

The demonstrated endpoint is cell collection in multiple myeloma, not direct tumor response.

Analysis detail

The label's central-laboratory analysis and published trial analysis report different percentages and should not be combined.

Identity

What it is

APHEXDA is the U.S. prescription product containing motixafortide. It is given with filgrastim before collection by apheresis.

FDA

Research

Research evidence

GENESIS compared motixafortide plus filgrastim with placebo plus filgrastim in adults preparing for autologous transplantation.

FDAPMID 37069359
Study / evidence areaPopulationDesignProduct contextMain outcomeLimitationsWeight
GENESIS
FDAPMID 37069359
122 adults with multiple myeloma preparing for autologous transplantationRandomized, double-blind, placebo-controlled phase 3 trialSubcutaneous motixafortide or placebo, both with filgrastimIn the label's central-laboratory analysis, 67.5% versus 9.5% reached at least 6 million CD34-positive cells per kg in up to two apheresis procedures after a single dose. Collection is not a direct cancer response or survival endpoint. The publication presents a different analysis with different percentages. Randomized evidence for a specific collection endpoint

Use context

Reported use context

The label and study schedule describe supervised transplant care. They are context for the evidence, not instructions for personal use.

FDAPMID 37069359

Study and label context

01
GENESIS and U.S. label contextSubcutaneous injection

The label specifies 1.25 mg/kg based on actual body weight, 10 to 14 hours before first apheresis after four days of filgrastim. A second dose may be given before a third apheresis if needed.

Label and study context only, not an individual recommendation.
FDA

Cautions

Safety and unknowns

  • The label requires pretreatment with an H1 antihistamine, an H2 blocker, and a leukotriene inhibitor before each dose, plus monitoring for one hour after injection. Anaphylactic shock was reported in clinical studies.
    FDA
  • APHEXDA is contraindicated in patients with a history of serious hypersensitivity to motixafortide.
    FDA
  • Injection-site reactions were common. The label also warns about leukocytosis, possible tumor cell mobilization and fetal harm, and advises against use for stem cell mobilization in leukemia patients.
    FDA

Product quality

Product identity and quality

The approved product is a sterile prescription injection prepared and administered by health professionals. Unrelated products cannot be assumed to have the same identity or quality.

FDA

Approved product and use

The label applies to APHEXDA and the specified transplant collection setting.

FDA

Mechanism

How it is proposed to work

Motixafortide blocks the CXCR4 receptor, interrupting a signal involved in keeping blood-forming stem cells in bone marrow.

FDA
01

CXCL12 binds CXCR4. Blocking that interaction helps increase the number of circulating cells available for collection.

FDA

FAQ

Common questions

Is motixafortide a treatment for multiple myeloma?

Its FDA indication is to mobilize stem cells with filgrastim for collection and subsequent autologous transplant, not to treat the cancer directly.

FDA

Details

Technical details

Motixafortide technical details
Name
Motixafortide / APHEXDA
Class
CXCR4 antagonist
Route
Subcutaneous injection
U.S. indication
Mobilization with filgrastim before autologous transplant in multiple myeloma

Sources

References

  1. 1.

    FDA. APHEXDA prescribing information

    U.S. indication, label dosing, central-laboratory collection analysis, and warnings.

  2. 2.

    PubMed. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

    doi:10.1038/s41591-023-02273-z PMID:37069359 NCT03246529

    Published GENESIS trial; its reported collection analysis differs from the FDA label analysis.

  3. 3.

    European Medicines Agency. EU orphan designation for motixafortide in patients undergoing haematopoietic stem cell transplantation

    Orphan designation is not a marketing authorization and does not establish current EU approval status.